| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery [T. F., T. M., W-W. Z., J. A. R.], and Departments of Tumor Biology [E. A. G.], Surgical Oncology [E. A. G.], and Immunology [L. B. O-S.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030
Recombinant adenovirus-mediated transfer of the wild-type p53 gene into monolayer cultures or multicellular tumor spheroids of human non-small cell lung cancer cell line H358, which has a homozygous deletion of p53, markedly increased the cellular sensitivity of these cells to the chemotherapeutic drug cisplatin. Treated cells underwent apoptosis with specific DNA fragmentation. Direct injection of the p53-adenovirus construct into H358 tumors s.c. implanted into nu/nu mice, followed by i.p. administration of cisplatin, induced massive apoptotic destruction of the tumors. These results support the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adenovirus and DNA-damaging drugs for treatment of human cancer.
1 This work was partially supported by Grant RO1 CA45187 from the National Cancer Institute (to. J. A. R.), Training Grants CA09611 (to J. A. R.) and CA45225 (to E. A. G.), gifts to the Division of Surgery from Tenneco and Exxon for the Core Lab Facility, the University of Texas M. D. Anderson Cancer Center Core Grant CA16672 and a generous gift from the Mathers Foundation.
2 To whom requests for reprints should be addressed, at Department of Thoracic Surgery, UT M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030.
Received 1/31/94. Accepted 3/18/94.
This article has been cited by other articles:
|
|
 |
|
  T. Sher, G. K. Dy, and A. A. Adjei Small Cell Lung Cancer Mayo Clin. Proc., March 1, 2008; 83(3): 355 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Tolcher, D. Hao, J. de Bono, A. Miller, A. Patnaik, L. A. Hammond, L. Smetzer, J. Van Wart Hood, J. Merritt, E. K. Rowinsky, et al. Phase I, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered Ad5CMV-p53, an Adenoviral Vector Containing the Wild-Type p53 Gene, in Patients With Advanced Cancer J. Clin. Oncol., May 1, 2006; 24(13): 2052 - 2058. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Fujiwara, N. Tanaka, S. Kanazawa, S. Ohtani, Y. Saijo, T. Nukiwa, K. Yoshimura, T. Sato, Y. Eto, S. Chada, et al. Multicenter Phase I Study of Repeated Intratumoral Delivery of Adenoviral p53 in Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., April 10, 2006; 24(11): 1689 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Strait, C. T. Warnick, C. D. Ford, B. Dabbas, E. H. Hammond, and S. J. Ilstrup Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad Mol. Cancer Ther., April 1, 2005; 4(4): 603 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Pisters, C. A. Pettaway, P. Troncoso, T. J. McDonnell, L. C. Stephens, C. G. Wood, K.-A. Do, S. M. Brisbay, X. Wang, E. A. Hossan, et al. Evidence That Transfer of Functional p53 Protein Results in Increased Apoptosis in Prostate Cancer Clin. Cancer Res., April 15, 2004; 10(8): 2587 - 2593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y Tsunemitsu, S Kagawa, N Tokunaga, S Otani, T Umeoka, J A Roth, B Fang, N Tanaka, and T Fujiwara Molecular therapy for peritoneal dissemination of xenotransplanted human MKN-45 gastric cancer cells with adenovirus mediated Bax gene transfer Gut, April 1, 2004; 53(4): 554 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ohtani, S. Kagawa, Y. Tango, T. Umeoka, N. Tokunaga, Y. Tsunemitsu, J. A. Roth, Y. Taya, N. Tanaka, and T. Fujiwara Quantitative analysis of p53-targeted gene expression and visualization of p53 transcriptional activity following intratumoral administration of adenoviral p53 in vivo Mol. Cancer Ther., January 1, 2004; 3(1): 93 - 100. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. S. Kim, M. Blake, J. H. Baek, G. Kohlhagen, Y. Pommier, and F. Carrier Inhibition of Histone Deacetylase Increases Cytotoxicity to Anticancer Drugs Targeting DNA Cancer Res., November 1, 2003; 63(21): 7291 - 7300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Moon, Y. Oh, and J. A. Roth Current Status of Gene Therapy for Lung Cancer and Head and Neck Cancer Clin. Cancer Res., November 1, 2003; 9(14): 5055 - 5067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Havrilesky, K. M. Darcy, H. Hamdan, R. L. Priore, J. Leon, J. Bell, and A. Berchuck Prognostic Significance of p53 Mutation and p53 Overexpression in Advanced Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study J. Clin. Oncol., October 15, 2003; 21(20): 3814 - 3825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Fukazawa, B. Walter, and L. B. Owen-Schaub Adenoviral Bid Overexpression Induces Caspase-dependent Cleavage of Truncated Bid and p53-independent Apoptosis in Human Non-small Cell Lung Cancers J. Biol. Chem., July 3, 2003; 278(28): 25428 - 25434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Huang, T. Tyler, N. Saadatmandi, C. Lee, P. Borgstrom, and R. A. Gjerset Enhanced Tumor Suppression by a p14ARF/p53 Bicistronic Adenovirus through Increased p53 Protein Translation and Stability Cancer Res., July 1, 2003; 63(13): 3646 - 3653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z.-q. Yuan, R. I. Feldman, G. E. Sussman, D. Coppola, S. V. Nicosia, and J. Q. Cheng AKT2 Inhibition of Cisplatin-induced JNK/p38 and Bax Activation by Phosphorylation of ASK1: IMPLICATION OF AKT2 IN CHEMORESISTANCE J. Biol. Chem., June 20, 2003; 278(26): 23432 - 23440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. P. Connell and R. R. Weichselbaum Gene Therapy: The Challenges of Translating Laboratory Research Into Clinical Practice J. Clin. Oncol., June 15, 2003; 21(12): 2230 - 2231. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Danesi, F. De Braud, S. Fogli, T. M. De Pas, A. Di Paolo, G. Curigliano, and M. Del Tacca Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer Pharmacol. Rev., March 1, 2003; 55(1): 57 - 103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Koivusalo, E. Krausz, P. Ruotsalainen, H. Helenius, and S. Hietanen Chemoradiation of Cervical Cancer Cells: Targeting Human Papillomavirus E6 and p53 Leads to Either Augmented or Attenuated Apoptosis Depending on the Platinum Carrier Ligand Cancer Res., December 15, 2002; 62(24): 7364 - 7371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Takenobu, K. Tomizawa, M. Matsushita, S.-T. Li, A. Moriwaki, Y.-F. Lu, and H. Matsui Development of p53 Protein Transduction Therapy Using Membrane-permeable Peptides and the Application to Oral Cancer Cells Mol. Cancer Ther., October 1, 2002; 1(12): 1043 - 1049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Oakley, E. Phillips, R. Hooper, D. Wilson, and M. Partridge A Preclinical Model of Minimal Residual Cancer in the Muscle Highlights Challenges Associated with Adenovirus-mediated p53 Gene Transfer Clin. Cancer Res., June 1, 2002; 8(6): 1984 - 1994. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Burg, K. Jensen-Pergakes, A. M. Gonzalez, P. Ravey, A. Baird, and D. Larocca Enhanced Phagemid Particle Gene Transfer in Camptothecin-treated Carcinoma Cells Cancer Res., February 1, 2002; 62(4): 977 - 981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Hu, J. Hofmann, Y. Lu, G. B. Mills, and R. B. Jaffe Inhibition of Phosphatidylinositol 3'-Kinase Increases Efficacy of Paclitaxel in in Vitro and in Vivo Ovarian Cancer Models Cancer Res., February 1, 2002; 62(4): 1087 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. F. Pollack, S. D. Finkelstein, J. Burnham, E. J. Holmes, R. L. Hamilton, A. J. Yates, J. L. Finlay, and R. Sposto Age and TP53 Mutation Frequency in Childhood Malignant Gliomas: Results in a Multi-institutional Cohort Cancer Res., October 1, 2001; 61(20): 7404 - 7407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nishizaki, R. E. Meyn, L. B. Levy, E. N. Atkinson, R. A. White, J. A. Roth, and L. Ji Synergistic Inhibition of Human Lung Cancer Cell Growth by Adenovirus-mediated Wild-Type p53 Gene Transfer in Combination with Docetaxel and Radiation Therapeutics in Vitro and in Vivo Clin. Cancer Res., September 1, 2001; 7(9): 2887 - 2897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schuler, R. Herrmann, J. L.P. De Greve, A. K. Stewart, U. Gatzemeier, D. J. Stewart, L. Laufman, R. Gralla, J. Kuball, R. Buhl, et al. Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results of a Multicenter Phase II Study J. Clin. Oncol., March 15, 2001; 19(6): 1750 - 1758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Rosenberg, M. M. Taher, N. B. Kuemmerle, J. Farnsworth, and K. Valerie A Truncated Human Xeroderma Pigmentosum Complementation Group A Protein Expressed from an Adenovirus Sensitizes Human Tumor Cells to Ultraviolet Light and Cisplatin Cancer Res., January 1, 2001; 61(2): 764 - 770. [Abstract] [Full Text]
|
|
|
|
 |
|
 Y. Nagayama, H. Yokoi, K. Takeda, M. Hasegawa, E. Nishihara, H. Namba, S. Yamashita, and M. Niwa Adenovirus-Mediated Tumor Suppressor p53 Gene Therapy for Anaplastic Thyroid Carcinoma in Vitro and in Vivo J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4081 - 4086. [Abstract] [Full Text]
|
|
|
|
|
|
J. Nemunaitis, I. Ganly, F. Khuri, J. Arseneau, J. Kuhn, T. McCarty, S. Landers, P. Maples, L. Romel, B. Randlev, et al. Selective Replication and Oncolysis in p53 Mutant Tumors with ONYX-015, an E1B-55kD Gene-deleted Adenovirus, in Patients with Advanced Head and Neck Cancer: A Phase II Trial Cancer Res., November 1, 2000; 60(22): 6359 - 6366. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Weill, M. Mack, J. Roth, S. Swisher, S. Proksch, J. Merritt, and J. Nemunaitis Adenoviral-Mediated p53 Gene Transfer to Non-small Cell Lung Cancer Through Endobronchial Injection Chest, October 1, 2000; 118(4): 966 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Coukos, A. Makrigiannakis, E. H. Kang, S. C. Rubin, S. M. Albelda, and K. L. Molnar-Kimber Oncolytic Herpes Simplex Virus-1 Lacking ICP34.5 Induces p53-independent Death and Is Efficacious against Chemotherapy-resistant Ovarian Cancer Clin. Cancer Res., August 1, 2000; 6(8): 3342 - 3353. [Abstract] [Full Text]
|
|
|
|
|
|
T. Itoshima, T. Fujiwara, T. Waku, J. Shao, M. Kataoka, W. G. Yarbrough, T.-J. Liu, J. A. Roth, N. Tanaka, and M. Kodama Induction of Apoptosis in Human Esophageal Cancer Cells by Sequential Transfer of the Wild-Type p53 and E2F-1 Genes: Involvement of p53 Accumulation via ARF-mediated MDM2 Down-Regulation Clin. Cancer Res., July 1, 2000; 6(7): 2851 - 2859. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. M. Albelda, R. Wiewrodt, and J. B. Zuckerman Gene Therapy for Lung Disease: Hype or Hope? Ann Intern Med, April 18, 2000; 132(8): 649 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Cabelguenne, H. Blons, I. de Waziers, F. Carnot, A.-M. Houllier, T. Soussi, D. Brasnu, P. Beaune, O. Laccourreye, and P. Laurent-Puig p53 Alterations Predict Tumor Response to Neoadjuvant Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Prospective Series J. Clin. Oncol., April 7, 2000; 18(7): 1465 - 1473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Bunn Jr., A. Soriano, G. Johnson, and L. Heasley New Therapeutic Strategies for Lung Cancer : Biology and Molecular Biology Come of Age Chest, April 1, 2000; 117 (2009): 163S - 168S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W. Lowe and A. W. Lin Apoptosis in cancer Carcinogenesis, March 1, 2000; 21(3): 485 - 495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Pearson, F. R. Spitz, S. G. Swisher, M. Kataoka, M. G. Sarkiss, R. E. Meyn, T. J. McDonnell, R. J. Cristiano, and J. A. Roth Up-Regulation of the Proapoptotic Mediators Bax and Bak after Adenovirus-mediated p53 Gene Transfer in Lung Cancer Cells Clin. Cancer Res., March 1, 2000; 6(3): 887 - 890. [Abstract] [Full Text]
|
|
|
|
|
|
J. Nemunaitis, S. G. Swisher, T. Timmons, D. Connors, M. Mack, L. Doerksen, D. Weill, J. Wait, D. D. Lawrence, B. L. Kemp, et al. Adenovirus-Mediated p53 Gene Transfer in Sequence With Cisplatin to Tumors of Patients With Non-Small-Cell Lung Cancer J. Clin. Oncol., February 1, 2000; 18(3): 609 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. H. Wilson, L. Sorbara, W. D. Figg, E. K. Mont, E. Sausville, K. E. Warren, F. M. Balis, K. Bauer, M. Raffeld, A. M. Senderowicz, et al. Modulation of Clinical Drug Resistance in a B Cell Lymphoma Patient by the Protein Kinase Inhibitor 7-Hydroxystaurosporine: Presentation of a Novel Therapeutic Paradigm Clin. Cancer Res., February 1, 2000; 6(2): 415 - 421. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Fan and J. R. Bertino Modulation of Cisplatinum Cytotoxicity by p53: Effect of p53-Mediated Apoptosis and DNA Repair Mol. Pharmacol., November 1, 1999; 56(5): 966 - 972. [Abstract] [Full Text]
|
|
|
|
|
|
G. L. Clayman, D. K. Frank, P. A. Bruso, and H. Goepfert Adenovirus-mediated Wild-Type p53 Gene Transfer as a Surgical Adjuvant in Advanced Head and Neck Cancers Clin. Cancer Res., July 1, 1999; 5(7): 1715 - 1722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Maurer, M. A. Ihnat, C. Morgan, J. Pullman, C. O'Brien, S. W. Johnson, J. S. Rasey, and M. M. Cornwell Growth of Human Tumor Cells in Macroporous Microcarriers Results in p53-Independent, Decreased Cisplatin Sensitivity Relative to Monolayers Mol. Pharmacol., May 1, 1999; 55(5): 938 - 947. [Abstract] [Full Text]
|
|
|
|
|
|
M. Nishizaki, T. Fujiwara, T. Tanida, A. Hizuta, H. Nishimori, T. Tokino, Y. Nakamura, M. Bouvet, J. A. Roth, and N. Tanaka Recombinant Adenovirus Expressing Wild-Type p53 Is Antiangiogenic: A Proposed Mechanism for Bystander Effect Clin. Cancer Res., May 1, 1999; 5(5): 1015 - 1023. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Ohashi, F Kanai, H Ueno, T Tanaka, K Tateishi, T Kawakami, Y Koike, T Ikenoue, Y Shiratori, H Hamada, et al. Adenovirus mediated p53 tumour suppressor gene therapy for human gastric cancer cells in vitro and in vivo Gut, March 1, 1999; 44(3): 366 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Schumacher, M. Kataoka, J. A. Roth, and T. Mukhopadhyay Potent Antitumor Activity of 2-Methoxyestradiol in Human Pancreatic Cancer Cell Lines Clin. Cancer Res., March 1, 1999; 5(3): 493 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Polverini and J.E. Nor Apoptosis and Predisposition To Oral Cancer Critical Reviews in Oral Biology & Medicine, January 1, 1999; 10(2): 139 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Muller, S. Wilder, D. Bannasch, D. Israeli, K. Lehlbach, M. Li-Weber, S. L. Friedman, P. R. Galle, W. Stremmel, M. Oren, et al. p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs J. Exp. Med., December 7, 1998; 188(11): 2033 - 2045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Perz and J. G. Kuhn Review : p53 in the pathogenesis, diagnosis, and treatment of cancer Journal of Oncology Pharmacy Practice, June 1, 1998; 4(2): 75 - 102. [Abstract] [PDF]
|
|
|
|
 |
|
 D. B. Zamble, T. Jacks, and S. J. Lippard p53-dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells PNAS, May 26, 1998; 95(11): 6163 - 6168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nagane, A. Levitzki, A. Gazit, W. K. Cavenee, and H.-J. S. Huang Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases PNAS, May 12, 1998; 95(10): 5724 - 5729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Mueller-Klieser Three-dimensional cell cultures: from molecular mechanisms to clinical applications Am J Physiol Cell Physiol, October 1, 1997; 273(4): C1109 - C1123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. McCurrach, T. M. F. Connor, C. M. Knudson, S. J. Korsmeyer, and S. W. Lowe bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis PNAS, March 18, 1997; 94(6): 2345 - 2349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Nguyen, F. R. Spitz, N. Yen, R. J. Cristiano, and J. A. Roth GENE THERAPY FOR LUNG CANCER: ENHANCEMENT OF TUMOR SUPPRESSION BY A COMBINATION OF SEQUENTIAL SYSTEMIC CISPLATIN AND ADENOVIRUS-MEDIATED p53 GENE TRANSFER J. Thorac. Cardiovasc. Surg., November 1, 1996; 112(5): 1372 - 1377. [Abstract] [Full Text]
|
|
|
|
|
|
N. L. Johnson, A. M. Gardner, K. M. Diener, C. A. Lange-Carter, J. Gleavy, M. B. Jarpe, A. Minden, M. Karin, L. I. Zon, and G. L. Johnson Signal Transduction Pathways Regulated by Mitogen-activated/Extracellular Response Kinase Kinase Kinase Induce Cell Death J. Biol. Chem., February 9, 1996; 271(6): 3229 - 3237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. F. Trump Mechanisms of Toxicity and Carcinogenesis Toxicol Pathol, November 1, 1995; 23(6): 775 - 827. [PDF]
|
|
|
|
 |
|
 S. Lowe, S Bodis, A McClatchey, L Remington, H. Ruley, D. Fisher, D. Housman, and T Jacks p53 status and the efficacy of cancer therapy in vivo Science, November 4, 1994; 266(5186): 807 - 810. [Abstract] [PDF]
|
|
|
|
|
|
B. F. Trump Mechanisms of Toxicity and Carcinogenesis: July 16-19, 1994, The Gant Conference Center, Aspen, Colorado Toxicol Pathol, November 1, 1994; 22(6): 658 - 686. [PDF]
|
|
|
|
 |
|
 S.W. Lowe, S. Bodis, N. Bardees, A. McClatchey, L. Remington, H.E. Ruley, D.E. Fisher, T. Jacks, J. Pelletier, and D.E. Housman Apoptosis and the Prognostic Significance of p53 Mutation Cold Spring Harb Symp Quant Biol, January 1, 1994; 59(0): 419 - 426. [Abstract] [PDF]
|
|
|
|
|
|
A.F. Gazdar, S. Bader, J. Hung, Y. Kishimoto, Y. Sekido, K. Sugio, A. Virmani, J. Fleming, D.P. Carbone, and J.D. Minna Molecular Genetic Changes Found in Human Lung Cancer and Its Precursor Lesions Cold Spring Harb Symp Quant Biol, January 1, 1994; 59(0): 565 - 572. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
